Acorai

What They Do

Non-invasive intracardiac pressure monitor for heart failure management. The device measures pressure inside the heart without invasive catheterization, enabling continuous monitoring of heart failure patients.^[1]

Funding

Valuation: ~€20-40M (€4.2M+ raised)

€2.3M seed round^[2]
€4.2M additional (December 2024), preparing to raise additional capital^[3]

Regulatory

Received FDA Breakthrough Device Designation for their non-invasive intracardiac pressure monitor.^[4] This designation accelerates the FDA review process for devices addressing unmet medical needs.

↑ TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"
↑ MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"
↑ Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"
↑ PR Newswire (2024): "Acorai receives Breakthrough Device Designation for their non-invasive intracardiac pressure monitor"

[1] TechCrunch (2023): "Heart failure monitoring startup Acorai turns heads with oversubscribed seed"

[2] MassDevice (2023): "Intracardiac pressure monitoring device startup Acorai raises €2.3M"

[3] Silicon Canals (Dec 2024): "Sweden's Acorai bags €4.2M to advance its heart failure management devices"

[4] PR Newswire (2024): "Acorai receives Breakthrough Device Designation for their non-invasive intracardiac pressure monitor"

[1]

[2]

[3]

[4]

Acorai

Contents

What They Do

Funding

Regulatory

See Also